UPADACITINIB (Rinvoq) prior authorization at Centene
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Centene requires Janus Kinase Inhibitor prior-authorization documentation for UPADACITINIB (Rinvoq): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Centene reviews UPADACITINIB (Rinvoq) prior authorizations against its medical policy for Janus Kinase Inhibitor. Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Janus Kinase Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Centene's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Marketplace network adequacy issues
- Medicaid step therapy
- Specialty drug exclusions
UPADACITINIB (Rinvoq)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- TNF-inhibitor failure documentation required (post-2021 JAK class warning)
- Indication restriction (RA vs PsA vs UC vs Crohn's vs AD vs AS vs nr-axSpA)
- Dose restriction (15mg vs 30mg vs 45mg)
- Specialty pharmacy network restriction
Brand: Rinvoq. Selective JAK1 inhibitor. Approved for RA, PsA, AS, nr-axSpA, atopic dermatitis, ulcerative colitis, Crohn's disease, and giant cell arteritis (April 2025). Subject to JAK-class boxed warning.
Manufacturer patient-assistance program: AbbVie Complete — relevant when a Centene denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus an applicable, current clinical source supporting UPADACITINIB (Rinvoq)for the patient's indication.
Medicare Advantage cases may have plan reconsideration and independent-review steps. Confirm the current level, forwarding rule, and any expedited pathway directly in the notice before selecting an escalation route.
Centene Medicare Advantage organization determinations operate under 42 CFR Part 422 Subpart D. The applicable decision period and any Independent Review Entity routing depend on the request type, current rule, and plan notice. Record the cited source and version, then verify the operational due date against the current notice and CMS materials before relying on it.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Centene denial on DenialHelp.
Contact Centene
- Provider portal: https://ambetterhealth.com/provider-resources
Frequently asked questions
What documentation does Centene need for UPADACITINIB (Rinvoq) prior auth?
Centene's typical PA packet for UPADACITINIB (Rinvoq): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Janus Kinase Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Centene?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for UPADACITINIB (Rinvoq) at Centene?
Preparation scenarios to check against the current notice and policy include: Marketplace network adequacy issues; Medicaid step therapy; Specialty drug exclusions. These are not measured frequency claims. For UPADACITINIB (Rinvoq), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Centene on UPADACITINIB (Rinvoq)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the UPADACITINIB (Rinvoq) PA packet
Open ApprovalHelp — generate a UPADACITINIB (Rinvoq) prior-auth packet tailored to Centene's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com